Market Research NewsNews

Immune Checkpoint Inhibitors Market Overview, Research Forecast 2019 With Therapeutic Application, Distribution Channel By AstraZeneca, Merck Group, Merck KGaA, Novartis AG, F. Hoffmann-La Roche, Incyte Corporation, Regeneron, Sanofi, Eli Lilly And More

Immune Checkpoint Inhibitors

Global immune checkpoint inhibitors market was valued at an estimated USD 11.71 billion in 2018 this value is projected to grow to USD 42.11 billion by 2026, registering a CAGR of 17.35% in the forecast period of 2019-2026. This rise in market value can be attributed to growing incidences of cancer cases worldwide.

Get Free Sample of This Market Information:

Market Definition: Global Immune Checkpoint Inhibitors Market

Immune checkpoint inhibitor is a type of treatment option that is used to regulate the immune system and helps in blocking the proteins on the tumor cells. These therapeutic drugs are used for targeted cancer treatments in advanced forms of cancer in patients.

Market Drivers:

  • Increasing levels of cancer incidences amongst the population globally; this factor is expected to act as a driver for the market growth
  • Increasing presence of reimbursement policies and increasing healthcare expenditure; this factor is expected to act as a driver for the market growth

Market Restraint:

  • Higher cost caused due to the high research and development costs associated with the development and production of products; this factor is expected to restrain the market growth

Key Market Competitors: Global Immune Checkpoint Inhibitors Market

Few of the market competitors currently in the market are AstraZeneca; Novartis AG; F. Hoffmann-La Roche Ltd; Merck & Co., Inc.; Merck KGaA; Incyte Corporation; Regeneron; Sanofi; Eli Lilly and Company; Fortress Biotech; Immutep; Pfizer Inc.; NewLink Genetics Corporation and Bristol-Myers Squibb Company.

Get TOC For Full Analysis Of Report:

Global immune checkpoint inhibitors market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of immune checkpoint inhibitors market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Segmentation: Global Immune Checkpoint Inhibitors Market

  • By Type
    • CTLA-4 Inhibitor
    • PD-1 Inhibitor
    • PD-L1 Inhibitor
  • By Therapeutic Application
    • Melanoma
    • Lung Cancer
    • Urothelial Carcinoma
    • Hodgkin Lymphoma
    • Squamous Cell Carcinoma
    • Blood Cancer
    • Others
  • By Distribution Channel
    • Retail Pharmacies
    • Hospital Pharmacies
  • By Geography
    • North America
  • Canada
  • Mexico
    • South America
  • Brazil
  • Argentina
  • Rest of South America
    • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Turkey
  • Belgium
  • Netherlands
  • Switzerland
  • Rest of Europe
    • Asia-Pacific
  • Japan
  • China
  • South Korea
  • India
  • Australia
  • Singapore
  • Thailand
  • Malaysia
  • Indonesia
  • Philippines
  • Rest of Asia Pacific
    • Middle East & Africa
  • South Africa
  • Egypt
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Rest of Middle East & Africa

Key Developments in the Market:

  • In February 2019, Merck & Co., Inc. announced that they had received US FDA approval for their immune checkpoint inhibitor “Keytruda” (pembrolizumab) for the treatment of advanced Merkel cell carcinoma (MCC).
  • In January 2019, F. Hoffmann-La Roche Ltd announced that they had received US FDA approval for “Tecentriq” (atezolizumab) in combination with bevacizumab, paclitaxel and carboplatin for the treatment of non-small cell lung cancer in advanced stages.
  • In October 2018, Regeneron announced that they had received US FDA approval for “Libtayo” (cemiplimab) for the treatment of advanced cutaneous squamous cell carcinoma.

Reasons to Purchase this Report

  • Current and future of global immune checkpoint inhibitors market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Want Full Report? Enquire Here:

About Us

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing . We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research
Toll Free: +1-888-387-2818


Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *